Loading...
•
Jun 30, 2021
Solid Biosciences Q2 2021 Earnings Report
Solid Biosciences reported Q2 2021 financial results and provided a business update.
Key Takeaways
Solid Biosciences reported collaboration revenue of $3.6 million for the second quarter of 2021, driven by their collaboration agreement with Ultragenyx. The company's research and development expenses increased to $15.5 million, and they ended the quarter with approximately $249 million in cash and investments.
Advanced clinical activities to prepare for the next patient to be dosed in the IGNITE DMD clinical trial of SGT-001, with next patient dosing anticipated in Q4 2021.
Progressed the next generation Duchenne gene therapy program, SGT-003.
Advanced the Duchenne collaboration with Ultragenyx.
Ended Q2 with approximately $249 million in cash and investments, providing a cash runway into Q4 2022.
Forward Guidance
The company expects that its cash, cash equivalents and available-for-sale securities will enable Solid to invest in its Duchenne gene therapy programs and capital expenditures into the fourth quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...